Murat Sönmezer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Murat Sönmezer has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Cem Somer Atabekoğlu
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
28 shared publications - Batuhan Özmen
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
27 shared publications - Yavuz Emre Şükür
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
24 shared publications - Bülent Berker
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
13 shared publications - Ruşen Aytaç
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey
11 shared publications - Meltem Sönmezer
Private Office-ATM İş Merkezi, Ankara, Türkiye, Obstetrics and Gynecology, Ankara, Turkey
8 shared publications
Latest Publications
- 30 September 2026
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 79 (3) , 284-291
Compacted Thin Endometrium and Reproductive Outcomes in Frozen Embryo Transfer
Background: Endometrial thickness (EMT) is a key predictor of success in frozen-thawed embryo transfer (FET), but a 'thin' endometrium often poses clinical dilemmas regarding cycle progression. Recent evidence suggests that endometrial compaction—a decrease in EMT after progesteroneexposure—may reflect physiological receptivity rather than pathological thinning. However, its prognostic value in patients with thin EMT on transfer day is not yet established.Objectives: To assess the impact of endometrial compaction on live birth rates (LBR) in women with thin EMT (
- 30 September 2026
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 79 (3) , 284-291
Compacted Thin Endometrium and Reproductive Outcomes in Frozen Embryo Transfer
Background: Endometrial thickness (EMT) is a key predictor of success in frozen-thawed embryo transfer (FET), but a 'thin' endometrium often poses clinical dilemmas regarding cycle progression. Recent evidence suggests that endometrial compaction—a decrease in EMT after progesteroneexposure—may reflect physiological receptivity rather than pathological thinning. However, its prognostic value in patients with thin EMT on transfer day is not yet established.Objectives: To assess the impact of endometrial compaction on live birth rates (LBR) in women with thin EMT (
- 9 June 2026
- Published by Academician Publishing
- p. 271-278
Fertilite Koruyucu Yöntemler
- 6 November 2025
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (2) , 231-259
Female fertility preservation: 25 years of progress, expanding indications and future prospects
BACKGROUND: There has been an unprecedented progress in the field of fertility preservation (FP) beginning in the late 1990s. Specifically, technological innovations, refinements in the protocols, and a deeper understanding of reproductive physiology have collectively contributed the increased success and utilization of FP methods. OBJECTIVE AND RATIONALE: The objectives of this review are: (i) to identify the most recent and significant advances in FP, and (ii) based on evidence, to provide a comprehensive and up-to-date source of contemporary FP management approaches to guide clinicians in critical decision-making. In addition to cancer treatments, the indications for FP have expanded to include various systemic conditions such as haematological, metabolic, genetic, and immunological disorders, as well as gonadal surgery and a wish to delay childbearing. Due to the introduction of random start ovarian stimulation protocols and use of anti-oestrogen agents along with ovarian stimulation drugs, coupled with increased success with oocyte cryopreservation, improvements in ovarian tissue cryopreservation and refinements of transplantation techniques, women can now benefit from various FP options through an individualized approach. SEARCH METHODS: We searched for peer-reviewed articles in PubMed, Embase, and Cochrane Library databases containing the key words: FP, ovarian ageing, chemotherapy, radiotherapy, embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation, and in vitro follicle growth, in the English-language literature from inception to May 2025. OUTCOMES: Cryopreservation of embryos have long been performed successfully in the field of ART. With the advent and widespread of use vitrification, the experimental tag was removed and oocyte cryopreservation was defined as a standard technique of FP. The applicability, success, and safety of random start ovarian stimulation protocols have been demonstrated in many studies including meta-analyses. Improvements in ovarian tissue cryopreservation outcomes have been reported with robotic surgery, use of neovascularizing extracellular matrix, and adjuvant pharmacotherapy. The use of GnRH analogues along with chemotherapy has been trialled as a way of avoiding the need for FP. Although the rate of premature ovarian insufficiency was reported to be lower in some patient populations treated this way, no improvements in live birth rates have been demonstrated. Among the emerging and future options are the use of ovarian tissue freezing and pharmacological approaches to delay menopause and reproductive ageing, non-suppressive gonadoprotective pharmacotherapy, in vitro gametogenesis and in vitro purging of cancer cells from ovarian tissue for cryopreservation. Animal studies have reported success with in vitro follicle growth, and progress is being made with human ovarian tissue. WIDER IMPLICATIONS: The evolution of FP techniques has profound implications for clinical practice, not only for individuals facing fertility-compromising treatments or conditions, but also for the potential deferral of reproductive ageing. The advent of in vitro primordial follicle growth and gametogenesis may further revolutionize the landscape of reproductive medicine and FP. REGISTRATION NUMBER: N/A.
- 6 November 2025
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (2) , 231-259
Female fertility preservation: 25 years of progress, expanding indications and future prospects
BACKGROUND: There has been an unprecedented progress in the field of fertility preservation (FP) beginning in the late 1990s. Specifically, technological innovations, refinements in the protocols, and a deeper understanding of reproductive physiology have collectively contributed the increased success and utilization of FP methods. OBJECTIVE AND RATIONALE: The objectives of this review are: (i) to identify the most recent and significant advances in FP, and (ii) based on evidence, to provide a comprehensive and up-to-date source of contemporary FP management approaches to guide clinicians in critical decision-making. In addition to cancer treatments, the indications for FP have expanded to include various systemic conditions such as haematological, metabolic, genetic, and immunological disorders, as well as gonadal surgery and a wish to delay childbearing. Due to the introduction of random start ovarian stimulation protocols and use of anti-oestrogen agents along with ovarian stimulation drugs, coupled with increased success with oocyte cryopreservation, improvements in ovarian tissue cryopreservation and refinements of transplantation techniques, women can now benefit from various FP options through an individualized approach. SEARCH METHODS: We searched for peer-reviewed articles in PubMed, Embase, and Cochrane Library databases containing the key words: FP, ovarian ageing, chemotherapy, radiotherapy, embryo cryopreservation, oocyte cryopreservation, ovarian tissue cryopreservation, and in vitro follicle growth, in the English-language literature from inception to May 2025. OUTCOMES: Cryopreservation of embryos have long been performed successfully in the field of ART. With the advent and widespread of use vitrification, the experimental tag was removed and oocyte cryopreservation was defined as a standard technique of FP. The applicability, success, and safety of random start ovarian stimulation protocols have been demonstrated in many studies including meta-analyses. Improvements in ovarian tissue cryopreservation outcomes have been reported with robotic surgery, use of neovascularizing extracellular matrix, and adjuvant pharmacotherapy. The use of GnRH analogues along with chemotherapy has been trialled as a way of avoiding the need for FP. Although the rate of premature ovarian insufficiency was reported to be lower in some patient populations treated this way, no improvements in live birth rates have been demonstrated. Among the emerging and future options are the use of ovarian tissue freezing and pharmacological approaches to delay menopause and reproductive ageing, non-suppressive gonadoprotective pharmacotherapy, in vitro gametogenesis and in vitro purging of cancer cells from ovarian tissue for cryopreservation. Animal studies have reported success with in vitro follicle growth, and progress is being made with human ovarian tissue. WIDER IMPLICATIONS: The evolution of FP techniques has profound implications for clinical practice, not only for individuals facing fertility-compromising treatments or conditions, but also for the potential deferral of reproductive ageing. The advent of in vitro primordial follicle growth and gametogenesis may further revolutionize the landscape of reproductive medicine and FP. REGISTRATION NUMBER: N/A.
- Open Access
- 3 September 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (3) , 195-203
Optimal leading follicle size for final oocyte maturation in POSEIDON group 3 and 4 poor responders undergoing assisted reproductive technology cycles
Undefined - Journal of the Turkish-German Gynecological Association
- 3 September 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (3) , 195-203
Open AccessOptimal leading follicle size for final oocyte maturation in POSEIDON group 3 and 4 poor responders undergoing assisted reproductive technology cycles
Undefined - Journal of the Turkish-German Gynecological Association
- 20 August 2025
- Published by Springer Nature in Reproductive Sciences
- Vol. 32 (10) , 3393-3399
Second Clinical Pregnancy Following Repeat Ovarian Tissue Transplantation in an Acute Leukemia Survivor: First Report and Literature Overview
- 20 August 2025
- Published by Springer Nature in Reproductive Sciences
- Vol. 32 (10) , 3393-3399
Second Clinical Pregnancy Following Repeat Ovarian Tissue Transplantation in an Acute Leukemia Survivor: First Report and Literature Overview
- Open Access
- 6 August 2025
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 38 (1) , 2542846
Can Uterine Septum be an Etiological Factor for Dysmenorrhea in Primary Infertile Patients?
The aim of this study is to investigate the association between uterine septum and dysmenorrhea and to assess the effect of hysteroscopic resection on the severity of dysmenorrhea. The study group (N:50) consisted of women who underwent hysteroscopic septum resection, and the control group (N:74) consisted of women who underwent diagnostic hysteroscopy and had no significant uterine pathologies. The presence and severity of dysmenorrhea were assessed by using a 10 cm visual analog scale (VAS). The main outcome measurement was the difference between preoperative and postoperative dysmenorrhea VAS scores. The mean preoperative VAS score was significantly higher in the study group than the control group (4.6 ± 2.6 cm vs. 3.2 ± 2.4 cm, respectively; p = 0.023). The rates of moderate to severe dysmenorrhea were 52% in the study group and 17.5% in the control group (p = 0.025). The mean dysmenorrhea VAS score of women with uterine septum was significantly improved in postoperative 3rd and 6th months when compared to the preoperative period (3.4 ± 2.4 cm and 3.1 ± 2.3 vs. 4.6 ± 2.6 cm, respectively; P1 = 0.025 and P2 = 0.003). Uterine septum seems to be an etiological factor for dysmenorrhea. Although there is no significant relationship between septum depth and dysmenorrhea severity, hysteroscopic resection of the uterine septum improves dysmenorrhea in the infertile study group.
- 6 August 2025
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 38 (1) , 2542846
Open AccessCan Uterine Septum be an Etiological Factor for Dysmenorrhea in Primary Infertile Patients?
The aim of this study is to investigate the association between uterine septum and dysmenorrhea and to assess the effect of hysteroscopic resection on the severity of dysmenorrhea. The study group (N:50) consisted of women who underwent hysteroscopic septum resection, and the control group (N:74) consisted of women who underwent diagnostic hysteroscopy and had no significant uterine pathologies. The presence and severity of dysmenorrhea were assessed by using a 10 cm visual analog scale (VAS). The main outcome measurement was the difference between preoperative and postoperative dysmenorrhea VAS scores. The mean preoperative VAS score was significantly higher in the study group than the control group (4.6 ± 2.6 cm vs. 3.2 ± 2.4 cm, respectively; p = 0.023). The rates of moderate to severe dysmenorrhea were 52% in the study group and 17.5% in the control group (p = 0.025). The mean dysmenorrhea VAS score of women with uterine septum was significantly improved in postoperative 3rd and 6th months when compared to the preoperative period (3.4 ± 2.4 cm and 3.1 ± 2.3 vs. 4.6 ± 2.6 cm, respectively; P1 = 0.025 and P2 = 0.003). Uterine septum seems to be an etiological factor for dysmenorrhea. Although there is no significant relationship between septum depth and dysmenorrhea severity, hysteroscopic resection of the uterine septum improves dysmenorrhea in the infertile study group.
- Open Access
- 10 June 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (2) , 130-141
Multiple sclerosis, urinary tract infections and infertility: a comprehensive scoping review
Multiple sclerosis, urinary tract infections and infertility: a comprehensive scoping review - Journal of the Turkish-German Gynecological Association
- 10 June 2025
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 26 (2) , 130-141
Open AccessMultiple sclerosis, urinary tract infections and infertility: a comprehensive scoping review
Multiple sclerosis, urinary tract infections and infertility: a comprehensive scoping review - Journal of the Turkish-German Gynecological Association
- Open Access
- 14 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (2) , 691
Correction: Safety and effectiveness of controlled ovarian stimulation and oocyte retrieval during prepubertal and peripubertal period
- 14 January 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (2) , 691
Open AccessCorrection: Safety and effectiveness of controlled ovarian stimulation and oocyte retrieval during prepubertal and peripubertal period
- 28 September 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (5) , 2305-2313
Ovarian tissue cryopreservation and transplantation as a natural means to delay menopause
Ovarian tissue cryopreservation and transplantation (OTCT) offers hope for preserving fertility and endocrine functions in patients undergoing gonadotoxic treatments. Advancements in techniques for the procedure have transformed OTCT from an experimental procedure into a viable option. There is a growing interest in utilizing OTCT to delay menopause and alleviate associated health issues. Menopausal transition affects women globally, leading to symptoms and long- term health risks. OTCT has the potential to restore endocrine functions, reducing menopause-related symptoms while mitigating health consequences such as osteoporosis and cardiovascular diseases. Although the use of OTCT for delaying menopause is not clinically proven, the discussion around shows potential for future utilization. In essence, the remarkable advancements in OTCT have bestowed upon us the ability to safeguard fertility and sustain the delicate endocrine functions of the ovaries. However, it is the tantalizing prospect of utilizing this technique to postpone menopause and alleviate its associated symptoms that truly captivates the imagination. Further research is imperative to substantiate the clinical efficacy of OTCT; nonetheless, its potential in menopausal therapy is both promising and warrants comprehensive exploration. This review highlights advancements and the feasibility of OTCT to postpone menopause as an alternative approach to currently used conventional menopause therapy methods.
- 28 September 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (5) , 2305-2313
Ovarian tissue cryopreservation and transplantation as a natural means to delay menopause
Ovarian tissue cryopreservation and transplantation (OTCT) offers hope for preserving fertility and endocrine functions in patients undergoing gonadotoxic treatments. Advancements in techniques for the procedure have transformed OTCT from an experimental procedure into a viable option. There is a growing interest in utilizing OTCT to delay menopause and alleviate associated health issues. Menopausal transition affects women globally, leading to symptoms and long- term health risks. OTCT has the potential to restore endocrine functions, reducing menopause-related symptoms while mitigating health consequences such as osteoporosis and cardiovascular diseases. Although the use of OTCT for delaying menopause is not clinically proven, the discussion around shows potential for future utilization. In essence, the remarkable advancements in OTCT have bestowed upon us the ability to safeguard fertility and sustain the delicate endocrine functions of the ovaries. However, it is the tantalizing prospect of utilizing this technique to postpone menopause and alleviate its associated symptoms that truly captivates the imagination. Further research is imperative to substantiate the clinical efficacy of OTCT; nonetheless, its potential in menopausal therapy is both promising and warrants comprehensive exploration. This review highlights advancements and the feasibility of OTCT to postpone menopause as an alternative approach to currently used conventional menopause therapy methods.
- 19 September 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (10) , 2823-2830
Safety and effectiveness of controlled ovarian stimulation and oocyte retrieval during prepubertal and peripubertal period
Purpose Is it safe and effective to perform controlled ovarian stimulation (COS) and oocyte retrieval (OR) in prepubertal and peripubertal patients? Methods In this retrospective cohort study, data of 20 pre-/peripubertal patients who underwent COS and OR for the purpose of oocyte cryopreservation (OC) between 2008 and 2023 were reviewed. Following COS, all OR procedures were performed transabdominally using a vaginal ultrasound probe. Ovarian reserve was assessed by serum FSH, LH, estradiol, AMH, and antral follicle counts (AFC) in all subjects. All mature oocytes were vitrified. Results Mean age of the patients was 15.05 ± 1.87, mean AMH was 0.84 ± 0.8 ng/ml, mean FSH was 6.39 ± 3.95 IU/L, mean estradiol was 61.6 ± 51.9 pg/ml, mean LH was 4.69 ± 3.46 IU/L, and mean AFC was 5.5 ± 5.82. Among the patients, 12 had regular menstrual cycle, 5 had irregular menstrual cycle, whereas 3 patients still did not have their menarche yet. The indications for OC were as follows: primary ovarian insufficiency (n = 7), ovarian surgery for ovarian tumors (n = 5) or ovarian torsion (n = 1), mosaic Turner syndrome (n = 2), acute lymphoblastic leukemia (n = 1) anaplastic B-cell lymphoma (n = 1), Ewing’s sarcoma (n = 1), Noonan syndrome (n = 1), and Thalassemia (n = 1). The mean number of oocytes retrieved, MII oocytes frozen, and maturation rate were 5.11 ± 5.0, 3.92 ± 4.48, and 75.1 ± 25.6%, respectively. Stepwise linear regression analysis demonstrated a positive correlation between AFC and number of total oocytes retrieved and number of MII oocytes. In the case diagnosed with Noonan syndrome, all 7 retrieved oocytes were MI and all frozen at MI phase. No patient had any complication related to COS or OR. Conclusion Even though number of the enrolled subjects is limited and mean AMH is lower in our cohort, we demonstrated that performing COS and OR is safe in pre-/peripubertal patients. If required, transabdominal route can be performed in this age group for OR. AFC appears as a prognostic factor for stimulation outcome in this age group. Pediatric patients or young adolescents at risk for primary ovarian insufficiency should not be discouraged from utilizing OC.
- 19 September 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (10) , 2823-2830
Safety and effectiveness of controlled ovarian stimulation and oocyte retrieval during prepubertal and peripubertal period
Purpose Is it safe and effective to perform controlled ovarian stimulation (COS) and oocyte retrieval (OR) in prepubertal and peripubertal patients? Methods In this retrospective cohort study, data of 20 pre-/peripubertal patients who underwent COS and OR for the purpose of oocyte cryopreservation (OC) between 2008 and 2023 were reviewed. Following COS, all OR procedures were performed transabdominally using a vaginal ultrasound probe. Ovarian reserve was assessed by serum FSH, LH, estradiol, AMH, and antral follicle counts (AFC) in all subjects. All mature oocytes were vitrified. Results Mean age of the patients was 15.05 ± 1.87, mean AMH was 0.84 ± 0.8 ng/ml, mean FSH was 6.39 ± 3.95 IU/L, mean estradiol was 61.6 ± 51.9 pg/ml, mean LH was 4.69 ± 3.46 IU/L, and mean AFC was 5.5 ± 5.82. Among the patients, 12 had regular menstrual cycle, 5 had irregular menstrual cycle, whereas 3 patients still did not have their menarche yet. The indications for OC were as follows: primary ovarian insufficiency (n = 7), ovarian surgery for ovarian tumors (n = 5) or ovarian torsion (n = 1), mosaic Turner syndrome (n = 2), acute lymphoblastic leukemia (n = 1) anaplastic B-cell lymphoma (n = 1), Ewing’s sarcoma (n = 1), Noonan syndrome (n = 1), and Thalassemia (n = 1). The mean number of oocytes retrieved, MII oocytes frozen, and maturation rate were 5.11 ± 5.0, 3.92 ± 4.48, and 75.1 ± 25.6%, respectively. Stepwise linear regression analysis demonstrated a positive correlation between AFC and number of total oocytes retrieved and number of MII oocytes. In the case diagnosed with Noonan syndrome, all 7 retrieved oocytes were MI and all frozen at MI phase. No patient had any complication related to COS or OR. Conclusion Even though number of the enrolled subjects is limited and mean AMH is lower in our cohort, we demonstrated that performing COS and OR is safe in pre-/peripubertal patients. If required, transabdominal route can be performed in this age group for OR. AFC appears as a prognostic factor for stimulation outcome in this age group. Pediatric patients or young adolescents at risk for primary ovarian insufficiency should not be discouraged from utilizing OC.